Target intelligence / Profile preview

Harmful gut bacterium

Molecular classification
Bacterium, Pathogen, Microorganism
01

Overview

"Harmful gut bacteria" is a **non-specific term** referring to any bacterial species within the gastrointestinal tract that can cause disease or disrupt normal physiological processes. These are also known as *pathogenic gut bacteria* or *intestinal pathogens*. Common examples include certain strains of *Clostridium perfringens*, *Staphylococcus* spp., and pathogenic strains of *Escherichia coli* (*E. coli*)[10]. These organisms can produce toxins, trigger inflammation, and lead to infections both locally in the gut and systemically if they translocate into the bloodstream[1][3]. The presence or overgrowth of harmful gut bacteria is associated with various diseases such as gastrointestinal infections, inflammatory bowel disease, sepsis, and may contribute to systemic conditions through immune activation or toxin release. Therapeutic strategies typically involve antibiotics targeted at the specific pathogen; however, indiscriminate use can lead to antibiotic resistance and disruption of beneficial commensal microbiota—resulting in dysbiosis with further health consequences[2][4]. Because "harmful gut bacteria" does not refer to a single molecular entity but rather a broad group defined by their negative impact on host health, it is not considered a canonical therapeutic target like an enzyme or receptor. Instead, interventions often aim at restoring microbial balance rather than targeting one specific molecule. **Note:** This entry is marked as incorrect for structured target databases because it lacks specificity—it refers collectively to many possible organisms rather than a unique molecular target.

Other names
Pathogenic gut bacteriaGut pathogensDisease-causing intestinal bacteriaIntestinal pathogens
02

Mechanism of action

Inhibition of bacterial cell wall synthesis (for beta-lactam antibiotics) Disruption of protein synthesis (for macrolides and tetracyclines) DNA replication inhibition (for fluoroquinolones)

03

Biological functions

InfectionToxin productionImmune system activationInflammation induction
04

Disease associations

InfectionInflammation (e.g., inflammatory bowel disease)Gastrointestinal disorders (e.g., diarrhea, colitis)Systemic diseases (e.g., sepsis)
05

Safety considerations

Antibiotic resistance[3]Disruption of beneficial microbiota leading to dysbiosis[2][4]
06

Interacting drugs

Antibiotics (general class; specific drugs depend on bacterial species)[3]

Beyond the preview

Go deeper on Harmful gut bacterium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harmful gut bacterium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call